These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36794374)

  • 1. Intravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns.
    Phakey S; Hall AJ; Lim LL
    Ophthalmic Epidemiol; 2024 Feb; 31(1):94-97. PubMed ID: 36794374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
    Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
    J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
    Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
    BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration.
    Seong HJ; Park YM; Kim J; Son KJ; Chung EJ
    Korean J Ophthalmol; 2022 Oct; 36(5):435-442. PubMed ID: 35989065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
    Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
    Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
    Bodénès F; Massé H; Lebreton O; Weber M
    J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.
    Finger RP; Xie J; Fotis K; Parikh S; Cummins R; Mitchell P; Guymer RH
    Clin Exp Ophthalmol; 2017 Mar; 45(2):143-151. PubMed ID: 27449314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia.
    Skelly A; Carius HJ; Bezlyak V; Chen FK
    Adv Ther; 2017 Dec; 34(12):2585-2600. PubMed ID: 29164480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.
    Sood S; Mandell J; Watane A; Friedman S; Parikh R
    JAMA Ophthalmol; 2022 Jul; 140(7):716-723. PubMed ID: 35708679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.